Role of incretin ‐based therapy in hospitalized patients with type 2 diabetes

Evidence about the treatment of hospitalized type  2 diabetes patients with incretin‐based therapy has emerged in the past 15 years. Based on this evidence, dipeptidyl peptidase‐4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed. In relation to use of glucagon‐like peptide ‐1 and glucagon‐like peptide‐1 receptor agonist, further research is required to help define their role in the inpatient setting.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Letter to the Editor Source Type: research